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ABSTRACT
Incidence rates have risen rapidly for esophageal and gastric cardia ade-
nocarcinomas. These cancers, arising at and around the gastroesophageal
junction (GEJ), share a poor prognosis. In contrast, there is no consensus
with respect to clinical staging resulting in possible adverse effects on treat-
ment and survival. The goal of this study was to provide more insight into the
genetic changes underlying esophageal and gastric cardia adenocarcinomas.
We have used comparative genomic hybridization for a genetic analysis of 28
adenocarcinomas of the GEJ. Eleven tumors were localized in the distal
esophagus and related to Barrett’s esophagus, and 10 tumors were situated in
the gastric cardia. The remaining seven tumors were located at the junction
and could not be classified as either Barrett-related, or gastric cardia. We
found alterations in all 28 neoplasms. Gains and losses were distinguished in
comparable numbers. Frequent loss (>25% of all tumors) was detected, in
decreasing order of frequency, on 4pq (54%), 14q (46%), 18q (43%), 5q
(36%), 16q (36%), 9p (29%), 17p (29%), and 21q (29%). Frequent gain
(>25% of all tumors) was observed, in decreasing order of frequency, on
20pq (86%), 8q (79%), 7p (61%), 13q (46%), 12q (39%), 15q (39%), 1q
(36%), 3q (32%), 5p (32%), 6p (32%), 19q (32%), Xpq (32%), 17q (29%),
and 18p (25%). Nearly all patients were male, and loss of chromosome Y was
frequently noted (64%). Recurrent high-level amplifications (>10% of all
tumors) were seen at 8q23–24.1, 15q25, 17q12–21, and 19q13.1. Minimal
overlapping regions could be determined at multiple locations (candidate
genes are in parentheses): minimal regions of overlap for deletions were
assigned to 3p14 (FHIT, RCA1), 5q14-21 (APC, MCC), 9p21 (MTS1/CDKN2),
14q31–32.1 (TSHR), 16q23, 18q21 (DCC, PI5) and 21q21. Minimal overlap-
ping amplified sites could be seen at 5p14 (MLVI2), 6p12–21.1 (NRASL3),
7p12 (EGFR), 8q23–24.1 (MYC), 12q21.1, 15q25 (IGF1R), 17q12–21 (ERBB2/
HER2-neu), 19q13.1 (TGFB1, BCL3, AKT2), 20p12 (PCNA), 20q12–13
(MYBL2, PTPN1), and Xq25. The distribution of the imbalances revealed
similar genetic patterns in the three GEJ tumor groups. However, loss of
14q31–32.1 occurred significantly more frequent in Barrett-related adeno-
carcinomas of the distal esophagus, than in gastric cardia cancers (P 5 0.02).
The unclassified, “pure junction” group displayed an intermediate position,
suggesting that these may be in part gastric cardia tumors, whereas the others
may be related to (short-segment) Barrett’s esophagus. In conclusion, this
study has, first, provided a detailed comparative genomic hybridization-map
of GEJ adenocarcinomas documenting new genetic changes, as well as can-
didate genes involved. Second, genetic divergence was revealed in this poorly
understood group of cancers.
INTRODUCTION
Analyses of cancer incidence data in the United States and Western
Europe revealed steadily rising rates over the past decades of adeno-
carcinomas of the esophagus and gastric cardia (1, 2). Overall, cancer
of the esophagus is increasing, and stomach cancer is decreasing.
However, when analyzed by histological type and subsite the picture
is very different. In the esophagus, squamous cell carcinoma rates
have remained stable, whereas a rapid increase of adenocarcinoma is
observed. In the stomach, cardia shows a very similar pattern to
adenocarcinoma of the esophagus, but pyloric-antrum cancer is de-
creasing. Both esophageal and gastric cardia adenocarcinomas arise
around the GEJ.3 Esophageal adenocarcinoma is strongly correlated
with Barrett’s esophagus. In Barrett’s esophagus, the squamous cell
epithelium has undergone metaplastic change to columnar epithelium
as a result of long-standing gastroesophageal reflux (3–5). Metaplastic
change has also been observed at the GEJ, which might explain the
rising frequency at this location (6). Intestinal metaplasia of the gastric
cardia has been reported, however, its relation with malignant trans-
formation is presently not clear (7).
GEJ adenocarcinomas share a poor prognosis, due to aggressive tumor
behavior, as well as late detection (8, 9). Adenocarcinomas of the GEJ
region disproportionately affect white men and less frequently occur
among women (1, 10). A 5–6-fold increase has been reported between
1970 and 1990 (11, 12). The simultaneously increased incidence at the
different locations suggest that adenocarcinomas of the GEJ are related.
Reflux disease has been suggested as an etiological factor not only in
esophageal adenocarcinoma, but also in cancer of the gastric cardia (13).
Recent epidemiological studies have focused on the role of diet and
cigarette smoking. It was found that smoking is a major risk factor for
GEJ carcinomas (14). Also, increased fat intake was found to be impor-
tant in esophageal and gastric cardia cancers (15, 16). In addition, an
increasing prevalence of obesity may have contributed to the upward
trends in GEJ adenocarcinomas (17).
Cytogenetic studies of series of both gastric and esophageal adenocar-
cinomas have shown frequent chromosomal rearrangement of 11p13–15
(18) and deletion of 3q (19). In a study of 37 adenocarcinomas in
Barrett’s esophagus and gastric cardia, loss of the Y chromosome seemed
a prominent feature (20). Furthermore, rearrangements were most fre-
quently seen of chromosome arms 1p, 3q, 11p, and 22q. Genetic abnor-
malities have been extensively documented in the, formerly common,
pyloric-antrum type of gastric cancer (e.g., gene amplification; Ref. 21).
Ranzani et al. (22) detected LOH at 5q, 11p, 17p, and 18q and, with a low
frequency, also at 7q and 13q. In these gastric cancers, deletions often
occur at the APC and MCC loci on 5q21 (23). Little is known of LOH in
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GEJ tumors. In a recent study of adenocarcinoma of the gastric cardia,
frequent allelic loss was seen on 3p, 4q, 5q, 8p, 9pq, 12q, 13q, 17p, and
18q (24). Blount et al. (25) reported that alleles in chromosomes 5q, 17p,
and 18q are involved in esophageal adenocarcinomas with high fre-
quency. Allelotyping studies of esophageal adenocarcinoma have been
constructed (26–28). They found frequent loss on 1p, 3q, 6q, 4pq, 5q, 9p,
12pq, 13q, 17p, and 18q. A few in situ hybridization studies have been
reported on GEJ adenocarcinomas. In an early study, loss of chromosome
Y and aneuploidy in gastric adenocarcinomas was shown (29). Hunter et
al. (30) reported a high percentage of chromosome Y loss in esophageal
adenocarcinoma. Krishnadath et al. (31, 32) described loss of chromo-
some Y, gain of chromosome 8, and loss of chromosome 17 in esopha-
geal adenocarcinoma. Recently, CGH of GEJ cancers was reported on
limited numbers of these neoplasms (33, 34). Gain of chromosome 20
was most frequently found. Furthermore, gain was seen on 6p, 7pq, 8q,
and 17q, and loss was observed on 4pq, 5q, and 18q.
We undertook a CGH study to address the following questions: (a)
what are the frequent unbalanced genetic abnormalities occurring in
GEJ adenocarcinomas? (b) are there differences in the genetic profiles
of Barrett-related esophageal adenocarcinomas versus gastric cardia
cancers? and (c) is it possible to assign candidate genes underlying
these neoplasms?
MATERIALS AND METHODS
Patient Material. We collected 28 adenocarcinomas of the GEJ (i.e., 11
esophageal, 10 gastric cardia, and 7 nonclassifiable cancers). The specimens
were fresh-frozen, except four paraffin-embedded samples. The esophageal
carcinomas were located in the distal esophagus in the presence of Barrett’s
transformed mucosa. The nonclassifiable tumors were situated at the GEJ, and
Barrett’s mucosa was not present. The gastric cardia cancers were clearly
localized in the proximal stomach. The majority of the GEJ specimens were
primary tumors (n 5 23), but cell lines (n 5 3; Ref. 35) and xenografts (n 5 2)
were included also (Table 1). Staging of the tumors was performed according
to the UICC classification (36).
CGH. The 28 specimens were microdissected to enrich for tumor cell
content ($75% of cells). Excised tumor material was minced using a fine
scalpel, and digested in extraction buffer [10 mM Tris/HCl (pH 8.0), 100 mM
NaCl, 25 mM EDTA, 0.5% SDS, and 300 mg/ml Proteinase K] at 37°C for
several hours. DNA was extracted with phenol-chloroform-isoamyl alcohol for
at least four times and subsequently precipitated in ethanol, according to
standard protocols. DNA was treated with RNase (20 mg/ml in 2 3 SSC) for
1 h at 37°C, precipitated, and dissolved overnight in sterile water at 55°C.
Concentration, purity, and molecular weight of the DNA was estimated using
both UV spectrophotometry and ethidium bromide-stained agarose gels with
control DNA series.
The CGH procedure was based on the protocol described by Kallioniemi et
al. (37) with few modifications, as described previously by us (38). Tumor
DNA was direct-labeled with FITC-dUTP, and control male DNA was labeled
with lissamine-dUTP (both from DuPont-NEN, Boston, MA) by nick-transla-
tion. Each labeled DNA (200 ng) and 10 mg of human Cot-1 DNA (Life
Technologies, Inc., Gaithersburg, MD), dissolved in 10 ml of hybridization
buffer (50% formamide/2 3 SSC/10% dextran sulfate), were hybridized to
normal male metaphases and incubated at 37°C for 4 days. Posthybridization
washes were performed with 2 3 SSC at 37°C, followed by 0.1 3 SSC at
60°C. Slides were counterstained with 4,6-diamidino-2-phenylindole (0.5 mg/
ml) in Vectashield antifade solution (Vector Laboratories, Inc., Burlingame,
CA).
Images of each of the three fluorochromes were collected using an epifluo-
rescence microscope (Leica DM, Rijswijk, the Netherlands) equipped with
three single excitation filters, a multibandpass dichroic mirror, a multiband
emission filter (P-1 filter set; Chroma Technology, Brattleborough, VT), and a
cooled CCD camera (Photometrics, Tucson, AZ). The green, red, and blue
images were collected sequentially by changing the excitation filter. Images
were saved using a routine built up in SCIL-Image (TNO, Delft, the Nether-
lands), implemented on a Power Macintosh 8100, and analyzed using QUIPS
XL software (Vysis, Downers Grove, IL). For the profiles, losses of DNA
sequences are defined as chromosomal regions where the mean green to red
fluorescence ratio and its 95% confidence interval is below 0.9, whereas gains
are defined as chromosomal regions where this ratio is above 1.1 (a 0.8–1.2
interval was used for the four paraffin-embedded samples). The threshold
values were based on measurements from a series of normal controls.
Table 1 Tumor/patient data
Tumor Age/sex Site Type Differentiation Stage (UICC)a Barrett
oe33 73/F Esophagus Cell lineb Poor T2/3N0M0 Yes
bp1 69/M Esophagus Primary Moderate T3N0M0 Yes
bp2 49/M Esophagus Primary Moderate T3N1M0 Yes
bp7 61/M Esophagus Primary Poor T3N1M1 Yes
bp11 68/M Esophagus Primary Poor T3N1M1 Yes
ba3 53/M Esophagus Primary Poor T3N0M0 Yes
ba7 63/M Esophagus Primary Moderate T1N0M0 Yes
ba10 53/M Esophagus Primary Moderate T3N1M1 Yes
ba13 65/M Esophagus Primary Poor T3N1M0 Yes
ba22 73/M Esophagus Primary Moderate T3N1M1 Yes
ba27 85/M Esophagus Primary T3N1M1 Yes
oe19 72/M Cardia Cell lineb Moderate T3N1M0 No
m2.1 76/M Cardia Xenograftc Moderate T2N2M0 No
ba1 63/M Cardia Primary Well T2N1M0 No
ba15 57/M Cardia Primary Moderate T2N1M0 No
ba18 54/M Cardia Primary Poor T3N1M0 No
ba23 75/M Cardia Primary Moderate T3N1M0 No
ba26 63/M Cardia Primary Poor T2N0M0 No
ba32 58/M Cardia Primary Poor T3N2M0 No
ba33 69/M Cardia Primary Moderate T2N0M0 No
ba34 75/F Cardia Primary Moderate T2N2M0 No
oe50 71/F Junction Cell lineb Poor T2/3N0M0 No
m4.1 54/M Junction Xenograftc Poor T3N2M1 No
ba11 59/M Junction Primary Poor T3N2M0 No
ba17 78/M Junction Primary Moderate T3N0M0 No
ba19 67/M Junction Primary Poor T3N2M0 No
ba20 44/M Junction Primary Poor T3N2M0 No
ba21 62/M Junction Primary Moderate T3N0M0 No
a Tumor-node-metastasis classification according to the UICC (36). Adenocarcinomas of the GEJ are classified as gastric cardia. It is important to note that in this classification
distal oesophageal adenocarcinomas are relatively overrated in comparison with gastric cancers.
b Obtained from the European Collection of Animal Cell Cultures.
c Derived from a regional lymph node metastasis.
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Statistical Evaluation. The two-tailed Fisher’s exact test was used for
comparison of genetic aberrations in the GEJ tumor groups.
RESULTS
Our investigation concerned the CGH evaluation of 28 GEJ
adenocarcinomas, (i.e., 11 esophageal, 10 gastric cardia, and 7
nonclassifiable cancers of the junction; Table 1). The esophageal
carcinomas were located in the distal esophagus in the presence of
Barrett’s transformed mucosa. The nonclassifiable tumors were
situated at the gastro-esophageal junction, and Barrett’s mucosa
was not present. The gastric cardia cancers were clearly localized
in the proximal stomach. We found multiple alterations in all 28
neoplasms, illustrating the genetic instability of gastrointestinal
adenocarcinomas (Fig. 1). Gains and losses were seen in compa-
rable numbers. Frequent loss ($25% of all tumors) was detected,
in decreasing order of frequency, on 4pq (54%), 14q (46%), 18q
(43%), 5q (36%), 16q (36%), 9p (29%), 17p (29%), and 21q
(29%). Frequent gain ($25% of all tumors) was observed, in
decreasing order of frequency, on 20pq (86%), 8q (79%), 7p
(61%), 13q (46%), 12q (39%), 15q (39%), 1q (36%), 3q (32%), 5p
(32%), 6p (32%), 19q (32%), Xpq (32%), 17q (29%), and 18p
(25%). Examples are illustrated in Fig. 2. Nearly all patients were
male, which is common in these cancers, and loss of chromosome
Y was frequently noted (64%). Recurrent high-level amplifications
(.10% of all tumors) were seen at 8q23–24.1, 15q25, 17q12–21,
and 19q13.1. The 15q and 19q amplifications have not been
reported in other human neoplasms before. Minimal overlapping
regions could be determined at multiple locations (Table 2; can-
didate genes are in parentheses): minimal regions of overlap for
losses were assigned to 5q14-21 (APC, MCC), 9p21 (MTS1/
CDKN2), 14q31–32.1 (TSHR), 16q23, 18q21 (DCC, PI5), and
21q21. Less frequent (21% of the tumors), but clearly present, was
a minimal deleted region on 3p14 (FHIT, RCA1). Minimal over-
lapping sites for gains could be seen at 5p14 (MLVI2), 6p12–21.1
(NRASL3), 7p12 (EGFR), 8q23–24.1 (MYC), 12q21.1, 15q25
(IGF1R), 17q12–21 (ERBB2/HER2-neu), 19q13.1 (TGFB1, BCL3,
AKT2), 20p12 (PCNA), 20q12–13 (MYBL2, PTPN1), and Xq25.
The genomic imbalances displayed similar distribution profiles in
the three GEJ-tumor groups. However, loss of 14q31–32.1 oc-
curred significantly more frequent in Barrett-related adenocarcino-
mas of the distal esophagus, than in gastric cardia cancers (Fisher’s
exact test, P 5 0.02). The unclassified, pure junction group of
tumors displayed an intermediate position (Fig. 3). It suggests that
part of these may be gastric cardia tumors, whereas the others may
be related to Barrett’s transformed mucosa (i.e., the so-called
short-segment Barrett’s esophagus).
DISCUSSION
This study reports the first detailed CGH-map of genetic changes
underlying adenocarcinomas of the GEJ. The overall genomic profile,
Fig. 1. Chromosomal ideograms showing the
summary of DNA copy number changes, detected
by CGH, in 28 adenocarcinomas of the GEJ
(esophagus, 11; gastric cardia, 10; junction/non-
classifiable, 7). Losses are displayed on the left of
the ideogram (red), gains are shown on the right
(green). Frequent loss is detected on 4pq, 5q, 9p,
14q, 16q, 17p, 18q, 21q, and Y. Frequent gain is
observed on 1q, 3q, 5p, 6p, 7p, 8q, 12q, 13q, 15q,
17q, 18p, 19q, 20pq, and Xpq.
Fig. 2. CGH of four GEJ adenocarcinomas il-
lustrating specific frequent deletions or high-level
amplifications. The chromosomal ideograms are
shown along with the ratio profiles and the digi-
tized fluorescent images. A, high-level amplifica-
tion of 8qter (MYC region) in an adenocarcinoma
of the junction (ba11; nonclassifiable). B, deletion
of 14q31–32.1 in an esophageal tumor cell line
(oe33). C, amplification of 15qter, including
15q25, in a gastric cardia cancer (xenograft m2.1);
also, a deletion is present, proximal from the am-
plification. D, high-level amplification of 19q13.1
(ba15; cardia carcinoma).
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and the distribution of the chromosomal alterations, is clearly different
from other frequently occurring human solid tumors, such as cancers
of the breast, lung, or prostate (reviewed in Refs. 39 and 40). A
number of new, not previously documented, genetic changes were
detected (e.g., loss on 14q and 16q, or gain of 5p and 13q). Other
aberrations were confirmed, such as loss on 4pq, 5q, and 18q, or gain
of 20pq and 8q. New high-level amplifications are reported (i.e., on
15q25 and 19q13.1), and minimal regions were determined at several
chromosomal sites. Furthermore, genetic divergence within GEJ ad-
enocarcinomas was disclosed. Below, we will discuss the most prev-
alent and/or relevant alterations, as well as candidate genes (Tumor
suppressor and oncogenes described below are reviewed in Refs.
41–43).
Chromosomal Losses. The most frequent loss seemed to involve
chromosome 4, the long arm slightly more than the short arm. This is
in agreement with previous molecular studies in which frequent LOH
on 4q was found (27). So, far, no genes have been implicated for the
deletion in this region.
About 50% of the neoplasms exhibited loss on 14q with a minimal
region at 14q31–32.1. This region is clearly different from the 14q
loss that is frequently encountered in gastrointestinal stromal tumors
(i.e., 14q22; Ref. 44). A possible candidate gene residing in our
chromosomal region is the TSHR, a gene involved in adenocarcino-
mas of the thyroid gland. Interestingly, this deletion points at genetic
divergence in GEJ cancers: Frequent loss (64%) was seen in Barrett-
related esophageal adenocarcinomas, but not in gastric cardia tumors
(10%; P 5 0.02). This might be associated with different cancer stem
cells in Barrett’s transformed esophageal mucosa, a condition not
known in the proximal stomach. The “unclassified” group displayed
an intermediate status (43% loss), which is possibly related to the
presence of a so-called short-segment Barrett’s esophagus (6).
The loss encountered on 3p14 (21% of the tumors) seems to involve
the FHIT gene. Recently, frequent deletions of FHIT were reported in
Barrett’s esophagus and adenocarcinoma (45). Some of the deleted
areas could be connected with known tumor suppressor genes, such as
MCC (5q21), MTS1 (9p21), or DCC (18q21), whereas other regions
might harbor yet unknown suppressor genes (i.e., 16q23 and 21q21).
We found loss on 17p in ;30% of the cancers. LOH of the p53 region
has been reported in varying frequencies in esophageal adenocarci-
noma (26, 27).
Chromosomal Gains. The most frequent gain occurred at chro-
mosome 20 (86% of all tumors), the long arm (20q12–13) being
slightly more altered than the short arm (20p12). The latter gain might
involve PCNA. Loss of 20q has been reported in various solid cancers
and was found associated with a poor prognosis in breast cancer (46).
Several candidate genes have been suggested, among them MYBL2 or
PTPN1, a nonreceptor tyrosine phosphatase involved in growth reg-
ulation (47).
Numerous gain (79%) was also seen of the long arm of chromo-
some 8 (see also “Amplifications”). Gain of 8q, often involving the
whole chromosome arm, is seen in many human cancers (e.g., prostate
cancer; Ref. 40). Other chromosomal areas, frequently gained, were
5p14, 6p12–21.1, 7p12, 12q21.1, and Xq25. The gain of 7p12 is likely
to be associated with the EGFR, a gene often involved in human
neoplasms. The gain of 5p14 might implicate a leukemia virus inte-
gration site (MLVI2), and 6p gain is possibly related to NRASL3,
which belongs to the RAS superfamily (47).
Amplifications. A distinction is made between gains and amplifica-
tions, as pointed out recently by Knuutila et al. (47). True amplifications,
likely representing chromosomal amplicons, are seen as a distinct and
high peak in the CGH profile of a given neoplasm. However, there is a
gray area between gain and amplification, which is clearly illustrated in
our series by the 7p12 region (EGFR). This site showed frequent and
specific gain, but no high-level amplification. We observed amplifica-
tions (.10% of all tumors) for the following chromosomal regions:
8q23–24.1, 15q25, 17q12–21, and 19q13.1. The 8q and 17q amplicons
are likely to be associated with, respectively, MYC and ERBB2, onco-
genes frequently involved in various cancers. However, the amplifica-
tions at 15q and 19q, possibly characteristic for GEJ adenocarcinomas,
are not easily attributed to a candidate gene because they have not been
described before as putative oncogenic sites.
The 15qter amplification might implicate the IGF1R gene, which
has been reported to be sporadically amplified in human breast cancer,
in some cases with coamplification of FES, residing at 15q26.1. (48).
The amplification at 19q31.1 could be associated with TGFb, BCL3,
or AKT2, a murine thymoma oncogene homologue (Table 2). How-
ever, further investigation is needed to elucidate the nature of the
chromosome 15 and 19 amplifications, which might play an important
role in GEJ cancers.
In conclusion, this study has revealed a variety of chromosomal
aberrations in GEJ cancers. Some of these changes might be found
in all types of cancer, whereas others might be associated with
epithelial neoplasms. The genomic patterns of the three GEJ tumor
types, revealed by CGH, are markedly similar, indicating that they
are a closely related entity. However, one genetic change (del14q)
was distinguished that varied between the three groups, suggesting
some degree of tissue specificity. Presently, we are further inves-
tigating this region by LOH analysis.4 Overall, the CGH profile of
4 B. P. L. Wijnhoven, unpublished data.
Fig. 3. Chromosome 14 ideograms demonstrating the prevalence of distal 14q deletions
(14q31–32.1) in the three GEJ groups. Note frequent loss in Barrett-related esophageal
adenocarcinomas, in contrast to gastric cardia tumors (P 5 0.02). The unclassified
junction tumors display an intermediate position.
Table 2 List of genes, potentially involved in frequent alterations (amp,a del) of
adenocarcinomas of the GEJ
CGH aberration Candidate gene Location Function
3p14 del FHIT 3p14.2 Suppression
RCA1 3p14.2 Suppression
5p14 amp MLV12 5p14 Activation (?)
5q14-21 del MCC 5q21 Suppression
APC 5q21-22 Suppression
6p12-21.1 amp NRASL3 6p12-ter Activation
7p12 amp EGFR 7p12 Activation
8q23-24.1 amp MYC 8q24.1 Activation
9p21 del MTS1 9p21 Suppression
14q31-32.1 del TSHR 14q31 Suppression
15q25 amp IGF1R 15q25-26 Activation (?)
17q12-21 amp HER2-neu 17q12-21 Activation
ERBB2
18q21 del DCC 18q21.3 Suppression
PI5 18q21.3 Suppression
19q13.1 amp TGFb1 19q13 Activation
BCL3 19q13 Activation
AKT2 19q13 Activation
20p12 amp PCNA 20p12 Activation (?)
20q12-13 amp MYBL2 20q13.1 Activation
PTPN1 20q13 Activation (?)
a amp, gain/amplification; del, deletion; RCA1, renal carcinoma, familial-associated
1;HER2-neu, V-erb-b2; PI5, protease inhibitor 5 (maspin).
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GEJ cancer is clearly different from other malignancies. Therefore,
the deletion of 14q31–32.1 or the amplifications at 15q25 and
19q13.1, might have diagnostic use for adenocarcinomas of the
GEJ.
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